LINC01816: A Drug Target / Disease Biomarker (G100133985)

Target Name: LINC01816

NCBI ID: G100133985

LINC01816

Other Name(s): long intergenic non-protein coding RNA 1816 | Long intergenic non-protein coding RNA 1816

LINC01816: A Drug Target / Disease Biomarker

LINC01816 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is found in various tissues and cells throughout the body and is involved in the regulation of gene expression.

Recent studies have suggested that LINC01816 may have a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target makes it an attractive target for researchers to investigate and develop new treatments.

One of the key reasons for the potential of LINC01816 as a drug target is its involvement in the regulation of gene expression. Genes are the fundamental units of genetic information that are responsible for the development and function of all living organisms. The regulation of gene expression is critical for the proper functioning of the body and is involved in the development and progression of many diseases.

LINC01816 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and modulating the activity of RNA polymerase, a protein that is responsible for transcribing DNA into RNA. This interaction between LINC01816 and RNA polymerase suggests that it may have a role in the regulation of gene expression and the development of diseases.

Another potential mechanism by which LINC01816 may contribute to the development of diseases is its role in the regulation of cellular signaling pathways. Signaling pathways are critical for the communication between cells and are involved in the regulation of many cellular processes, including cell growth, differentiation, and inflammation.

LINC01816 has been shown to play a role in the regulation of cellular signaling pathways by binding to specific protein targets and modulating the activity of signaling pathways. This suggests that it may have a role in the development and progression of diseases by contributing to the regulation of cellular signaling pathways.

In addition to its potential role in the regulation of gene expression and cellular signaling pathways, LINC01816 has also been shown to play a role in the regulation of inflammation. Chronic inflammation is a risk factor for the development of many diseases, including autoimmune disorders and neurodegenerative diseases.

LINC01816 has been shown to play a role in the regulation of inflammation by binding to specific immune cell populations and modulating their activity. This suggests that it may have a role in the development and progression of diseases by contributing to the regulation of inflammation.

Overall, the potential of LINC01816 as a drug target and biomarker makes it an attractive target for researchers to investigate and develop new treatments for a variety of diseases. Further studies are needed to fully understand its role in the regulation of gene expression, cellular signaling pathways, and inflammation.

Protein Name: Long Intergenic Non-protein Coding RNA 1816

The "LINC01816 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01816 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets